Kodiak Sciences reports Q2 EPS (86c), consensus (87c)

Ended Q2 with $219.2M of cash and cash equivalents, believes that current cash will support our current and planned operations into 2026. “Our three clinical programs of tarcocimab, KSI-501 and KSI-101 are making strong operational progress,” said Victor Perlroth, CEO. “The Phase 3 GLOW2 study of tarcocimab in diabetic retinopathy continues to enroll. The Phase 3 DAYBREAK study of tarcocimab and KSI-501 is now actively enrolling patients. DAYBREAK features an innovative study design that includes parallel investigational arms of tarcocimab and KSI-501 against aflibercept in wet AMD, and if successful, could support the marketing authorization applications for both investigational medicines. We have also activated the Phase 1b APEX study of KSI-101 in patients with macular edema secondary to inflammation, and the APEX study is now enrolling patients.”